

Special Issue

Chimeric Antigen Receptor (CAR) T-cells: A Revolution in Immunotherapy

Message from the Guest Editor

Chimeric antigen receptor T-cell (CAR-T) therapies have demonstrated remarkable potential in the treatment of different cancer types, especially hematological malignancy. Despite its high clinical response rate, CAR-T treatment still faces critical challenges such as antigen escape, on-target off-tumor toxicities, and immune suppression. There is an urgent need to overcome these limitations in order to expand CAR-T applications. To achieve a more extensive understanding of recent scientific knowledge and current trends in CAR-T therapy development, this Special Issue focuses on recent scientific and technical progress in this field, especially in the endeavor to conquer the aforementioned challenges. We invite authors to contribute original reports, original observations, or reviews that highlight (i) target selection, (ii) strategies to overcome current CAR-T limitations, (iii) the mechanisms/cellular pathways behind the limitations, and (iv) recent advances in novel CAR-T development.

Guest Editor

Dr. Jiawei Wang

1. Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA
2. Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA

Deadline for manuscript submissions

closed (31 December 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/159944

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).